JOHN MARAGANORE
CIK 1180432 · Chief Executive Officer · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$69.15M
Companies
10
Total Filings
122
Lifetime Open-Market Net
-$121.06M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TAK | Director | 13,800 | $17.75 | $244.9K | $0 | 1 | 2026-07-06 |
| KYMR | Director | — | $105.25 | — | $0 | 5 | 2026-06-25 |
| RAPP | Director | — | $40.94 | — | $0 | 2 | 2026-06-10 |
| BEAM | Director | — | $26.02 | — | $0 | 6 | 2026-06-05 |
| COAG | Director | 35,948 | $44.75 | $1.61M | $0 | 1 | 2026-05-04 |
| PROK | Director | — | $1.54 | — | $0 | 1 | 2023-07-03 |
| AGIO | Director | 30,028 | $35.01 | $1.05M | -$1.80M | 18 | 2022-06-23 |
| ALNY | Chief Executive Officer | 231,115 | $286.62 | $66.24M | -$114.58M | 77 | 2021-12-23 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 1,236 | $4.97 | $6.1K | -$4.68M | 9 | 2017-09-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 51,254 | $8.16 | $418.2K | $0 | 1 | 2012-10-11 |
Recent Filings · Page 11 of 13
122 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-12-21 | ALNY | Mixed | +18,617 | $8.8K | EDGAR |
| 2012-10-11 | Regulus Therapeutics Inc. (RGLS) Delisted | Conv (C) | +6,150,500 | $0 | EDGAR |
| 2012-02-23 | ALNY | Buy (P) | +5,581 | $60.0K | EDGAR |
| 2012-01-11 | ALNY | Buy (P) | +1,134 | $10.0K | EDGAR |
| 2011-12-14 | ALNY | Buy (P) | +1,397 | $10.0K | EDGAR |
| 2011-12-02 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2011-11-16 | ALNY | Buy (P) | +1,411 | $10.0K | EDGAR |
| 2011-10-13 | ALNY | Mixed | −1,020 | $10.0K | EDGAR |
| 2010-12-10 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2010-08-18 | ALNY | Exer (M) | +50,000 | $23.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.